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ABSTRACT 
 
 
[Purpose] 
 
TMEPAI is a direct target gene of transforming growth factor-β (TGF-β)/Smad 
signaling, and participates in the negative feedback regulation to control the duration 
and intensity of TGF-β/Smad signaling. In this thesis work, I aimed to investigate the 
mechanism of enhanced TMEPAI expression in cancer cells and examined the 
cooperative roles of TGF-β and EGF signaling. In addition, I further aimed to 
investigate the tumorigenic activities of TMEPAI in lung cancer cells.  
 
 
[Materials and methods] 
 
We carried out experimental methods in molecular biology such as polymerase chain 
reaction (PCR), western-blotting, immunoprecipitation (IP), chromatin 
immunoprecipitation (ChIP) to examine the expression, phosphorylation and 
interactions of the proteins. The luciferase-reporter assays were used to examine the 
transcriptional activity of the target genes. TMEPAI was knockdown in lung cancer 
cells by short hairpin RNA, and sphere formation assay was used to examine oncogenic 
activities of these cells. For in vivo tumorigenic activity, two xenograft models, 
subcutaneous injection and tail vein injection were used.  
 
 
[Results] 
 
Lung adenocarcinoma cell lines Calu3, NCI-H23, and RERF-LC-KJ constitutively 
expressed TMEPAI and it was significantly suppressed by a TGF-β receptor kinase 
inhibitor SB208, suggesting that constitutive expression of TMEPAI in these cancer 
cells depends on autocrine TGF-β stimulation. Additionally, expression of TMEPAI in 
these cancer cells was significantly suppressed by MEK inhibitor U0126 too. TGF-β 
  
and EGF signals cooperatively enhanced the transcription of TMEPAI, suggesting that 
the EGFR/Ras/MAPK pathway is also involved in the regulation of TMEPAI in cancer 
cells. There are ELK-1 binding sites in the first intron of the TMEPAI gene. EGF-
induced activation of wild-type ELK-1, but not the mutant ELK-1S383A potentiated the 
TGF-β-induced transcription of the TMEPAI gene. Furthermore, the chromatin 
immunoprecipitation (ChIP) assay revealed that ELK-1 binds to the enhancer sequence 
in the first intron of the TMEPAI gene in response to EGF signaling.  
  Knockdown of TMEPAI in Calu3 cells enhanced levels of Smad2 phosphorylation and 
significantly suppressed cell proliferation in the presence of TGF-β. Furthermore, 
knockdown of TMEPAI in Calu3 cells and NCI-H23 cells suppressed sphere formation 
in vitro and tumor formation both in subcutaneous tissues and in lungs of NOD-SCID 
mice. Together, these results indicate that TMEPAI promotes tumorigenic activities in 
lung cancer cells. 
  Moreover, we recently identified that AktSer473 phosphorylation is suppressed in 
TMEPAI knockdown lung cancer cells, and the phosphatase working on this Akt 
residue PHLPP1 were increased in these TMEPAI knockdown cells.   
 
 
[Discussion] 
 
Cancer cells frequently have abnormal activation of EGF/Ras/MAPK signaling and 
TGF-β signaling. Deregulation of both signaling has been reported to contribute to 
cancer progression. Here, we showed that EGF/Ras/MEK and TGF-β signaling 
cooperatively control TMEPAI expression. On the other hand, knockdown of TMEPAI 
in lung cancer cells potentiated TGF-β-inducible Smad phosphorylation and growth 
inhibitory response to TGF-β. Consequently, the sphere-forming activity, subcutaneous 
tumor formation, and lung metastasis were suppressed. Moreover, we identified that 
AktSer473 phosphorylation is suppressed in TMEPAI knockdown lung cancer cells. 
Akt phosphatase PHLPP1 increased in these cells. These data suggest a possibility of 
novel function of TMEPAI, which is independent from the Smad regulator function, 
may also contribute to the oncogenic function of TMEPAI.   
 
  
 
[Conclusion] 
 
In this work, we revealed that the expression of TMEPAI is transcriptionally enhanced 
by the cooperation between TGF-β/Smad and EGF/Ras/MAPK signals. TMEPAI has 
tumorigenic activities in lung cancer cells and it might be exerted by suppression of the 
TGF-β/Smad signaling and activation of the AKT signaling.    
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CHAPTER 1: INTRODUCTION 
 
 
1-1 Transforming growth factor β (TGF-β) signaling 
 TGF-β was identified almost 30 years ago as a factor that induced anchorage-
independent growth of normal rat kidney fibroblasts. Over the past decades, 33 
members of TGF-β family ligands have been identified in human comprising the TGF-
βs, bone morphogenetic proteins (BMPs), growth differentiation factors (GDFs), inhibin 
and activins (Roberts and Sporn et al., 1990; Massagué, 2000). All TGF-β family 
ligands are generated as dimeric precursor proteins and subsequently processed by 
proteases and secreted.   
 TGF-β signaling is initiated by ligand-induced heteromeric complex formation of 
specific type I and type II serine/threonine kinase receptors (TβRI and TβRII). TβRI 
(also termed activin receptor-like kinase-5; ALK5) is phosphorylated and activated by 
TβRII. Active TβRI catalyzes the C-terminal serine phosphorylation of receptor-
regulated Smads (R-Smads). Among R-Smads, Smad2 and Smad3 act downstream of 
TGF-β, activin, and nodal type I receptors; whereas Smad1, Smad5, and Smad8 act 
downstream of bone morphogenetic protein (BMP) type I receptors. After 
phosphorylation, R-Smads form a ternary complex with common mediator Smad (Co-
Smad, i.e., Smad4), and translocate into the nucleus, where they regulate, together with 
other partner proteins, the transcription of specific target genes (Massagué, 2000, Shi 
and Massagué, 2003). Inhibitory Smads (I-Smads, i.e. Smad6 and Smad7) can inhibit 
the activation of R-Smads by competing with R-Smads for interaction with type I 
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receptors and by recruiting specific ubiquitin ligases or phosphatases to the activated 
receptor complex, thereby targeting it for proteosomal degradation or dephosphorylation, 
respectively (Heldin et al., 1997; Shi and Massagué, 2003).  
 
 
 
 
Figure 1: Transforming Growth Factor β (TGF-β) signaling. After ligand-induced 
heteromeric TGF-β receptor complex formation, R-Smads (i.e., Smad2 and Smad3) are 
recruited to the activated TGF-β type I receptor and getting phosphorylated. Activated R-Smads 
form complexes with Smad4, which translocate to the nucleus, where they bind to the cis-
elements of the target genes, together with transcription factor(s) (TF) and coactivator(s), and 
activate transcription of the various target genes. 
 
 The TGF-β family members have diverse effects on a wide variety of cellular 
activities, including cell cycle control, extracellular matrix formation, apoptosis, 
angiogenesis, immune function, and cancer progression (Whitman, 1998; Massagué et 
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al., 2000; Derynck et al., 2001). The multiple functions of the TGF-β family members 
require tight control of their activities (Massagué and Wotton, 2000). Both positive and 
negative regulators have been identified at nearly every step in the TGF-β family 
signaling cascade. For example, Smad anchor for receptor activation (SARA) has been 
shown to recruit R-Smads to the activated TGF-β receptor complex (Moustakas and 
Heldin, 2009). On the other hand, I-Smads (i.e., Smad6 and Smad7), Smad 
ubiquitination regulatory factors (Smurfs), TG-interacting factor (TGIF), and ski-related 
novel protein N (SnoN) are direct target genes for TGF-β signaling and contribute to 
form negative feedback loops (Massagué et al., 2005; Itoh and ten Dijke, 2007). 
Misregulation of their functions has been implicated in the development of diseases 
such as cancer, fibrosis and autoimmune disease. 
 
1-2    TGF-β signaling and cancer  
 There are numerous studies about the role of TGF-β signaling in human cancers. 
TGF-β1 has been reported that it is frequently upregulated in tumor cells, and the 
transgenic mice that produce a constitutively active form of TGF-β1 have been shown 
to be resistant to DMBA induced tumor formation. Mutation in TGFBR1 and TGFBR2 
genes occur frequently in many cancers such as ovarian, breast, lung, esophageal, and 
prostate cancers (Derynck et al., 2001; Massagué, 2008). TGF-β can act as tumor 
suppressor in early stage and switch to tumor promoter in late stage (Pardali and 
Moustakas, 2007). During early stage of carcinogenesis, TGF-β acts as a tumor 
suppressor by inhibiting growth and promoting apoptosis. TGF-β downregulates c-Myc 
expression, which is required for the induction of p15 and p21 CDK inhibitors. TGF-β 
could also suppress the expression of ID1, which causes enhancement of Ras-driven 
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mammary tumorigenesis in mice, suggesting the tumor-suppressive role of TGF-β. 
Moreover, TGF-β can trigger apoptosis via inducing death-associated protein kinase 
DAPK, and Daxx adaptor protein through their ability to interact with TβRII (Massagué, 
2008). In addition, the role of TGF-β in angiogenesis during embryonic development 
has been well-documented. Ablation of TβRI or TβRII genes results in embryonic 
lethality because of angiogenesis defection suggesting that TGF-β can induce 
angiogenesis (ten Dijke and Arthur, 2007). Nevertheless, TGF-β has been shown to be 
upregulated in many human cancers and associated with poor prognosis, which suggests 
the tumor promoter function of TGF-β in late stage. Loss of TβRII expression increases 
the invasiveness of lung cancer cells (Toonkey et al., 2010). Furthermore, TGF-β is 
known as a potent inducer of epithelial to mesenchymal transition (EMT), which is 
characterized by extensive changes in the expression of cell adhesion molecules such as 
E-cadherin, N-cadherin, ZO-1, etc. TGF-β promotes EMT by inducing the expression of 
Snail, Slug, Twist, and metalloproteinases MMP2, MMP9, which are implicated in the 
migratory and invasive processes (Davies et al., 2005; Miyazono, 2009). Taken together, 
TGF-β is strongly implicated in cancer progression by modulating multiple aspects of 
tumorigenesis, including cell growth, apoptosis, angiogenesis, invasion and metastasis.   
 
1-3 Transmembrane prostate androgen induced protein (TMEPAI) 
 Transmembrane prostate androgen induced protein (TMEPAI), alternatively termed 
PMEPA1, STAG1, ERG1.2, or N4wbp4, is originally identified as a prostatic RNA, 
which is induced by testosterone or its derivatives (Xu et al., 2000, 2003; Giannini et al., 
2003). Transcription of TMEPAI gene was later shown to be induced by TGF-β 
(Brunschwig et al., 2003; Itoh et al., 2003; Levy and Hill, 2005). TMEPAI is a 
- 5 - 
 
transmembrane protein containing two PY motifs that can interact with HECT-type E3 
ubiquitin ligases (Li et al., 2008).  
 
Figure 2: Schematic representation of TMEPAI. There are one isoform in mouse and four 
isoforms in human (isoform a, b, c, d), which is different in the N terminus. The TMEPAI 
protein contains transmembrane domain (TM) and one Smad interaction motif (SIM) locating 
between two PY motifs (PY).    
 
 TMEPAI has been reported to be involved in p53-mediated apoptosis and cell growth 
inhibition (Xu et al., 2003). A recent report indicated that TMEPAI is a direct target 
gene of TGF-β signaling, which can interact with Smad2 and Smad3 via its Smad 
interaction motif to sequester Smads from TGF-β/Smad signaling. Because of the 
competition with SARA for binding to Smads, TMEPAI participates in a negative 
feedback regulation to control the intensity and duration of TGF-β/Smad signaling 
(Watanabe et al., 2010). In addition to TGF-β stimulation, TMEPAI has been reported to 
be induced by treatment with androgen, introduction of mutant p53, or activation of the 
ERK pathway (Xu et al., 2000; Anazawa et al., 2004). TMEPAI expression was highly 
increased in breast cancer, colon cancer, and renal cell carcinoma tissues as well as in 
many cancer cell lines suggesting an oncogenic function of this molecule. Actually, 
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TMEPAI was indicated as a “molecular switch” that converts TGF-β signaling from a 
tumor suppressor to a tumor promoter (Prajial et al., 2010). A recent study also shown 
that TMEPAI is a downstream target of Wnt signaling, in which the Wnt/β-
catenin/TCF7L2 pathway is preferentially able to activate the transcription of this gene 
(Nakano et al., 2010). Taken together, TMEPAI may play an important role in TGF-β 
signal regulation, highly expressed in cancer and contribute to cancer progression.  
 
 
 
Figure 3: Scheme of TMEPAI regulatory action on TGF-β signaling. TMEPAI is a target 
gene of the TGF-β/Smad signaling. After induced by TGF-β, TMEPAI locates in the cell 
membrane and interact with R-Smads (Smad2/3). Thus, TMEPAI sequesters R-Smads from 
TGF-β/Smads signaling. Thereby, TMEPAI regulates the duration and intensity of TGF-β 
signaling.  
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1-4 Epidermal growth factor (EGF) signaling  
 
1-4-1 Epidermal growth factor (EGF) signaling  
 Epidermal growth factor (EGF) is a key growth factor in regulating cell proliferation, 
cell survival, invasion and angiogenesis (Jorissen et al., 2003). Dysfunction of EGF 
signaling pathways is frequently observed in cancer and is involved in the pathogenesis 
and progression of cancers (Yarden, 2001; Henson and Gibson, 2006). Overexpression 
of EGFR has been occurred in many cancers and contributes to poor prognosis 
(Selvaggi et al., 2004; Lo et al., 2006). The epidermal growth factor receptor (EGFR) 
belongs to the ErbB family of receptor tyrosine kinases (RTKs), which comprises four 
distinct receptors, EGFR (HER-1/ErbB1), HER-2 (ErbB2 or Neu), HER-3/ErbB3, and 
HER-4/ErbB4. Upon binding to their ligands, EGF receptors form either homodimers or 
heterodimers, and subsequent autophosphorylation by its intracellular tyrosine kinase 
activity. Receptor activation leads to the activation of downstream signaling cascades 
including the RAS/extracellular signal regulated kinase (ERK) pathway, the Janus 
kinase/Signal transducer and activator of transcription (JAK/STAT) pathway, and the 
phosphotidylinositol 3-kinase/AKT (PI3K/AKT) pathway (Darnel et al., 1994; Jorissen 
et al., 2003; Quesnelle et al., 2007).  
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Figure 4: Epidermal Growth Factor (EGF) Signaling. Upon ligand-binding, the receptors 
form dimers and cause tyrosine phosphorylation by the intracellular tyrosine kinase domain. 
Receptor activation leads to activation of downstream signaling pathways, including 
Ras/Raf/MEK/ERK, Jak/STAT, and PI3K/AKT signaling pathways. 
 
1-4-2 RAS/MAPK signaling 
 Mitogen-activated protein kinases (MAPKs) are a family of protein serine-threonine 
kinases that is activated by receptor tyrosine kinases (RTKs), including EGF receptor. 
MAPKs consists extracellular signal-regulated kinase (ERK), c-jun terminal kinase 
(JNK), and p38-mitogen activated protein kinase. ErbB receptor activates ERK through 
the binding of adaptor protein Grb2 and/or Shc, then activates small G protein Ras. 
Activated Ras then phosphorylates and activates their downstream cascades Raf, MEK, 
ERK, respectively, leading to the activation of a variety of transcription factors, such as 
c-Myc, Tal1, and ELK-1, and consequently increase expression of their target genes  
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(Shaw and Saxton, 2003). Mutations in Ras gene, causing activation of Ras/MAPK 
signaling pathways, have been reported in many human cancers, such as pancreas, lung 
adenocarcinoma, melanoma, thyroid carcinoma, and so on (Downward, 2003).  
 
 
1-5  ELK-1 transcription factor 
 The E-twenty six (ETS) domain transcription factors including ELK-1, Net (ELK-3), 
and Sap-1 (ELK-4) belong to the ternary complex factor (TCFs) family of transcription 
factors to form a ternary nucleoprotein complex with the serum response factor (SRF) in 
regulating c-fos gene expression. The ETS domain transcription factors play a pivotal 
role in cell proliferation, differentiation, and development (Marais et al., 1993; Shaw 
and Saxton, 2003; Buchwalter et al., 2004). An ETS domain transcription factor ELK-1 
is a direct substrate of MAPK. Activation of ELK-1 triggers the regulation of a subset of 
genes involved in transcription, splicing, and translation (Janknecht et al., 1993; 
Wasylyk et al., 1998). Activation of ELK-1 has been reported in T-cell activation and 
development. Moreover, knockdown ELK-1 inhibits c-fos induction in the forebrain 
formation in mice, but not in embryonic fibroblast (MEFs). In addition, a shorter 
isoform of ELK-1 (sELK-1) with a truncation of 54-amino-acid from the N-terminal, 
has been shown to play an opposite role to ELK-1 in regulation of neuronal cell 
differentiation (Araud et al., 2007; Rahim et al., 2012). ELK-1 shares four conserved 
binding domains with other TCF family proteins: the N-terminal ETS DNA binding 
domain, which binds specifically to the purine-rich sequence 5`-GGA(A/T)-3` ETS 
binding site (EBS), SRF binding domain (B-box) that is responsible for the ternary 
complex formation, a MAPKs induced-transcriptional activation domain in the C-
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terminal end, and a MAPK binding domain. Moreover, a repressor domain (R motif), 
uniquely found in ELK-1, suppresses the transcriptional activity of ELK-1 and dampens 
its response to MAPK-inducible activation (Shore et al., 1995; Yang et al., 2002, 2003). 
Phosphorylation of ELK-1 by MAPK-1 triggers the conformational change resulting in 
enhancement of DNA binding activity and recruitment of coactivators such as CBP, 
p300, Srb, and consequently induces the regulation of the target genes.  
 
 
 
Figure 5: Representative structure of ELK-1. ELK-1 is one of TCF subfamily members. 
ELK-1 contains DNA binding ETS domain (A box), SRF binding domain (B box), MAP kinase 
binding domain (D box and F box), transcriptional activation domain (C box), and repressor 
domain (R box). 
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CHAPTER 2: 
Cooperative Induction of Transmembrane Prostate Androgen 
Induced protein-TMEPAI by Transforming Growth Factor-β and 
Epidermal Growth Factor signaling   
 
 
 
2-1  Introduction 
 It has been well-known that the transforming growth factor β (TGF-β) keeps pivotal 
role in regulating tissue homeostasis. Deregulation of TGF-β signaling has been 
implicated in many diseases, including cancer (Massagué et al., 2000, 2008). On the 
other hand, the TGF-β signaling has been interwoven into a vast network of cell 
signaling (Kretzchmar et al., 1999; Lo et al., 2001; Derynck and Zhang, 2003; Guo and 
Wang, 2009, Moustakas and Heldin, 2009). The epidermal growth factor (EGF) 
signaling is involved in signaling crosstalk with TGF-β signaling, and is important 
pathway in cancer progression. Numerous reports have described the co-operation 
between EGF/Ras/MAPK pathway and TGF-β signaling (Mulder, 2000; Freytag et al., 
2010). For instance, cells harboring oncogenic Ras mutations often confer resistance to 
growth inhibitory response to TGF-β. Activation of Ras via ERK/MAPK kinases causes 
linker phosphorylation of Smad2/3, leading to inhibit the nuclear translocation of Smads 
and their abilities to mediate TGF-β function (Mulder, 2000). Furthermore, Ras/MAPK 
pathway causes a decrease of Smad4 expression, inhibits TGF-β-induced complex 
formation between Smad2/3 and Smad4, and results in suppression of TGF-β signaling 
(Saha et al., 2001). In addition, Watanabe et al. reported that TGF-β-induced TMEPAI 
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participates in a negative feedback loop to regulate the activity of TGF-β signaling 
(Watanabe et al., 2010). Moreover the expression of TMEPAI is regulated not only by 
TGF-β signaling, but also by the other signaling pathways, for example EGF signaling 
and Wnt signaling (Giannini et al., 2003; Anazawa et al., 2004; Hirokawa et al., 2007, 
Nakano et al., 2010). However, the mechanism in which TMEPAI is regulated by EGF 
signaling still remains unclear. In this study, I aimed to investigate the regulation of 
TMEPAI by cooperation between TGF-β and EGF signaling. 
 
 
2-2  Materials and methods 
2-2-1 Plasmid construction. Human ELK-1 and the mutant ELK-1 S383A constructs 
were described previously (Araud et al., 2007). The luciferase constructs pGL3ti-1972-
luc, pGL3ti-250, pGL3ti-850, and Flag-Smad3 were described previously (Nakano et al., 
2010). The pGL3ti-250 mutants (pGL3ti-250-M1, pGL3ti-250-M2, pGL3ti-250-M123) 
were made by introducing the mutations to change the consensus sequence GGAT to 
TGCT by using corresponding mutant primers and pfx polymerase (Invitrogen). All 
plasmids were sequenced before use. 
 
2-2-2 Cell culture. HaCaT cells (spontaneously immortalized human keratinocyte cell 
line), HaCaT-mock, constitutively active H-Ras transformed HaCaT-RasG12V and 
COS7 cells (African green monkey kidney cells transformed by SV40) were cultured in 
Dulbecco`s modified Eagle’s medium (Sigma) containing 10% fetal calf serum (FCS, 
Invitrogen) and penicillin streptomycin solution. HepG2 cells were cultured in 
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minimum essential medium (Sigma) containing 10% FCS, non-essential amino acids 
(NEAA, Invitrogen), penicillin streptomycin solution, and sodium pyruvate. A TGF-β 
receptor kinase inhibitor SB431542 (Sigma) and a MEK kinase inhibitor U0126 (Wako) 
were used to block TGF-β signaling and EGF/Ras/MAPK signaling, respectively.  
 
2-2-3 Luciferase assay. HepG2 cells were seeded at 1.5 x 10
5
 cells/ well in 12-well 
plate one day before transfection. The cells were transfected using FuGENE6 (Roche 
Applied Science). Where indicated, the cell were stimulated with TGF-β (0.1 ng/ml) 
and EGF (10 ng/ml) 24 hours after transfection, and cultured in the absence of FCS for 
18 hours. Luciferase activities were determined by Luciferase Assay Systems 
(Promega) and normalized to β-galactosidase activity of co-transfected pCH110 (GE 
HealthCare). Each transfection was carried out in triplicate.  
 
Lysis buffer  : 2 mM DTT, 25 mM Tris-phosphate (pH 7.8), 
 2 mM trans-1,2-diaminocyclohexane-N,N,N`,N`-tetra-
acetic 
 acid monohydrate, 10% glycerol, 1% Triton X-100 
2x β-gal : 200 mM sodium phosphate buffer (pH 7.3), 
 100 mM β-mercaptoethanol, 
 1.33 mg/ml 2-nitrophentl-β-D-galactopyraniside 
   
2-2-4 Immunoprecipitation and western-blotting. To detect the protein-protein 
interaction, the plasmids were transfected into COS7 cells (5 x 10
5
 cells/ 6 cm dish) 
using FuGENE6. Thirty six hours after transfection, the cells were dissolved in 500 µl 
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of TNE lysis buffer. The cell lysates were precleared with protein G-Sepharose beads 
(GE Healthcare) for 30 minutes at 4
0
C with end-over-end rotation and then precipitated 
with Flag-antibody for 2 hours at 4
0
C. The immune complexes were precipitated by 
incubation with protein G-Sepharose beads for 30 minutes at 4
0
C, followed by 3 washes 
with TNE buffer. The immunoprecipitated proteins and aliquots of the total cell lysates 
were subjected to western-blotting. The membranes were probed with different primary 
antibodies and then incubated with horseradish peroxidase-conjugated secondary 
antibodies and chemiluminescent substrate solution (Thermo Scientific).  
 
TNE buffer : 10 mM Tris (pH 7.4), 150 mM NaCl, 10 mM EDTA, 
  1% NP-40, 1 mM PMSF, 20 mM β-glycerophosphate, 
 40 mM NaF, 100 units/ ml aprotinin, 5 µg/ml leupeptin. 
Western-blotting: 
SDS-PAGE  : <Separating gel> distilled water 6.1ml,  
polyacrylamide (10%) 30%  acrylamide solution (Wako) 6.1 ml, 
 2 M Tris (pH 8.8) 4.2 ml, 10% SDS 64 µl, 10% APS 58 µl,  
 N-N-N-N-tetramethyl-ethylenediamine (Wako) 13 µl  
 <Stacking gel> 20% glycerol 3.5 ml 
 30% acrylamide (Wako) 700 µl, 0.5 M Tris (pH 6.8) 700 µl, 
 10% SDS 25 µl, 10% APS 25 µl,  
 N-N-N-N-tetramethyl-ethylenediamine (Wako) 5 µl  
2x sample buffer  : 4% SDS, 1.44 M β-mercaptoethanol, 20% glycerol,  
 125 mM Tris (pH 7.4), 0.002% bromophenol blue 
TBST : 150 mM NaCl, 10 mM Tris (pH 7.4), 0.1% Tween20. 
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1
st
 antibody :  mouse anti-TMEPAI antibody (x 1000) 
 (homemade monoclonal antibody) (Vo Nguyen et al., 2014) 
 mouse anti-β-actin antibody (Sigma) (x 5000) 
 mouse anti-Erk 1/2 antibody (Zymed Ca) (x 1000)  
 mouse anti-phosphorylated Erk1/2 (pErk1/2) antibody  
(Cell Signaling) (x 1000)  
 rabbit anti-Smad2/3 antibody (BD Bioscience) (x 1000) 
 rabbit anti-phosphorylated Smad2 (PS2) antibody   
(Persson et al., 1998) (x 1000) 
 mouse anti-HA (3F10) antibody (Roche) (x 1000) 
  mouse anti-Flag M5 antibody (Sigma) (x 1000) 
2
nd
 antibody  : anti mouse-IgG-(horseradish peroxidase; HRP) 
 (GE Healthcare) (x 10000) 
 anti rabbit-IgG-HRP (GE Healthcare) (x 10000) 
 
2-2-5 Chromatin immunoprecipitation assay. HaCaT cells were stimulated with 
TGF-β (0.1 ng/ml) and EGF (10 ng/ml) as indicated for 1 hour, fixed by adding 
formaldehyde to the medium to a final concentration of 1% for 15 minutes at room 
temperature, and glycine was added to a final concentration of 125 mM. Then, the cells 
were washed with PBS once and collect into lysis buffer, and sonicated until the 
average length of input DNA became less than 500 bp in size. Then, the control IgG, 
anti-ELK-1, or anti-Smad3 was used for the precipitation of shared chromatins. The 
immunoprecipitated DNAs were purified and subjected to PCR amplification with 
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specific primers for detection of the TMEPAI promoter including ELK-1 binding 
elements.   
 
Lysis buffer  : 50 mM Tris-HCl (pH 8.0), 10 mM EDTA,  
 1% SDS, 10 µg/ml leupeptin, 12.5 µg/ml aprotinin 
Antibody  : rabbit anti-ELK-1 antibody (abcam) 
 rabbit anti-Smad3 antibody (Cell Signaling) 
 anti-rabbit IgG antibody  
Primer sequence:  5`-TGA GCG TGT CCA TCT TTC TG- 3` 
 5`-CAG TCC CAA ACA CAA ACA GC- 3`. 
 
 
 
2-3  Results 
2-3-1 Cooperative enhancement of TMEPAI expression by EGF in the presence of 
TGF-β. Human keratinocyte cell line HaCaT was stimulated with TGF-β, EGF, or both 
TGF-β and EGF. As shown in Fig. 6A, TMEPAI expression could be induced upon 
TGF-β stimulation, whereas there was no detectable level of TMEPAI upon EGF 
stimulation. However, co-stimulation with EGF clearly enhanced TMEPAI expression 
in the presence of TGF-β. Furthermore, HaCaT-RasG12V cells, in which constitutively 
active H-Ras was stably expressed, were used to confirm the contribution of EGF 
signaling on TMEPAI expression. Enhanced expression of TMEPAI was detected upon 
8 hours of TGF-β stimulation in HaCaT-RasG12V cells approximately 5 fold higher 
than that in HaCaT-mock cells (Fig. 6B). These data suggest that EGFR/Ras/MAPK 
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signaling is involved in the regulation of TMEPAI expression in the presence of TGF-β 
signaling (Azami S., 2011). 
 
 
 
 
 
 Figure 6: Cooperative Induction of TMEPAI by TGF-β and EGF signaling. (A) HaCaT 
cells were stimulated with TGF-β (0.5 ng/ml) and/or EGF (10 ng/ml) for 8 hours, as indicated. 
TMEPAI expression was detected by anti-TMEPAI antibody. β-actin was used as the loading 
control. (B) HaCaT-mock cells and HaCaT-RasG12V cells were stimulated with TGF-β (0.5 
ng/ml) for indicated times. Total cell lysates were subjected to western-blotting using an anti-
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TMEPAI antibody. β-actin was used as the loading control. Relative expression levels of 
TMEPAI/β-actin were detected by densitometry and indicated below the panels.  
(This figure was done by Azami S.) 
 
 
2-3-2 MEK inhibitor suppresses TMEPAI expression enhanced by EGF. TGF-β 
receptor kinase inhibitor SB41542 totally suppressed the expression of TMEPAI 
induced by both TGF-β and EGF, on the other hand MEK inhibitor U0126 suppressed 
the expression of TMEPAI down to the level obtained by TGF-β alone (Fig. 7A). 
Treating  HaCaT-RasG12V cells by U0126 in the presence of TGF-β stimulation 
resulted in the reduction of TGF-β-induced TMEPAI in a dose-dependent manner (Fig. 
7B). These data indicate that EGF signaling through the EGFR/Ras/MEK pathway 
contributes to the enhanced expression of TMEPAI (Azami S., 2011). 
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Figure 7: EGF/Ras/MAPK pathway enhances TGF-β induced-TMEPAI expression. (A) 
TGF-β receptor kinase inhibitor SB431542 (1 µM) or MEK kinase inhibitor U0126 (1 µM) was 
added 1 hour before stimulation with EGF (10 ng/ml), TGF-β (0.5 ng/ml), or both EGF (10 
ng/ml) and TGF-β (0.5 ng/ml) for 8 hours, as indicated. The cell lysates were subjected to 
western-blotting. TMEPAI was detected by using anti-TMEPAI antibody. β-actin was used as 
the loading control. (B) HaCaT-HRasG12V cells were treated with MEK inhibitor U0126, as 
indicated 1 hour before TGF-β (0.5 ng/ml) stimulation for 8 hours. Cell lysates were subjected 
to western-blotting and detected with anti-TMEPAI antibody. The levels of phosphorylated 
ERK, total ERK, phosphorylated Smad2, Smad2 and HA-HRasG12V were also detected to 
examine the effects of TGF-β and U0126 treatments. β-actin was used as the loading control.    
(This figure was done by Azami S.) 
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2-3-3 Identification of EGF responsiveness in the first intron of the TMEPAI gene. 
TMEPAI 5’ promoter luciferase reporter, termed -1972TMEPAI-Luc (Fig. 8A), and a 
TMEPAI first intron luciferase reporter, termed pGL3ti-850-Luc (Fig. 8C) were used 
for the identification of the EGF responsive elements upon EGF, TGF-β, or both EGF 
and TGF-β stimulation. The activity of -1972TMEPAI-luc was marginally enhanced by 
these stimulation (Fig. 8B). On the other hand, the activity of the pGL3ti-850-Luc was 
highly activated by TGF-β, and that was further potentiated by the addition of EGF (Fig. 
8D). Additionally, EGF potentiated the pGL3ti-850-Luc activities induced by TGF-β in 
dose-dependent manner (Fig. 8E). Furthermore, cotransfection of ELK-1, a transcription 
factor that is activated by EGFR/Ras/MEK pathway, significantly activated the pGL3ti-
850 reporter but ELK-1(S383A), which cannot be phosphorylated by Ras/MAPK 
pathway, did not (Fig. 8F). These data suggest that EGF potentiates the enhancer 
activities in the first intron of the TMEPAI gene through the activation of ELK-1 
(Azami S., 2011). 
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Figure 8: The first intron of TMEPAI gene contains the responsive sequences for TGF-β 
and EGF. (A) Schematic representation of the TMEPAI 5’-promoter luciferase reporter 
construct pGL3-TMEPAI (-1972/+67). The nucleotide numbers of mouse TMEPAI gene was 
shown with the transcriptional initiation site as +1. (B) Both EGF and TGF-β marginally 
enhanced the pGL3-TMEPAI(-1972/+67) luciferase activities in HepG2 cells. (C) Schematic 
representation of pGL3ti-850 reporter containing the +447 to +1294 sequence from the first 
intron of the TMEPAI gene. (D) HepG2 cells were transfected with pGL3ti or pGL3ti-850 and 
stimulated with EGF (10 ng/ml), TGF-β (0.1 ng/ml), or both EGF (10 ng/ml) and TGF-β (0.1 
ng/ml) for 18 hours. (E) HepG2 cells were transfected with pGL3ti-850 and treated with EGF 
for 18 hours with indicated concentrations in the presence or absence of TGF-β (0.1 ng/ml) 
stimulation. (F) HepG2 cells were transfected with pGL3ti-850 together with ELK-1 or ELK-
1(S383A), as indicated. Cells were stimulated with EGF (10 ng/ml) or TGF-β (0.1 ng/ml) for 18 
hours. (*P < 0.05) 
(This figure was done by Azami S.) 
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2-3-4 ELK-1 binding elements are required for the EGF-inducible enhancement of 
the TMEPAI gene expression. Stimulation by TGF-β increases the pGL3ti-850-Luc 
activity and co-stimulation by TGF-β and EGF made further activation of pGL3ti-850-
Luc. In parallel, the shorter region pGL3ti-250 containing the 250 bp sequence from 
+1037 to +1294 responded to TGF-β and EGF as similar manner with pGL3ti-850 (Fig. 
9A, 9B). I could find three ELK-1 binding consensus sequences (5`-GGAT-3` or 5`-
GGAA-3`) in the 250 bp sequence of the first intron. Mutation for each of ELK-1 
binding sites, or all three ELK-1 binding sites into pGL3ti-250-Luc reduced 
transcriptional responses upon EGF and TGF-β stimulation. Among them, the second 
mutant at position +1077 completely suppressed EGF-inducible enhancement of 
pGL3ti-250-Luc activity suggesting that this is the major binding element for ELK-1 in 
250 bp sequence (from +1037 to +1294) in the first intron of TMEPAI gene (Fig. 9C).   
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Figure 9: ELK-1 binding elements in the 250 bp (+1037/+1294) region of the first intron of 
the TMEPAI gene is essential for the response to EGF. (A) Schematic representation of the 
luciferase reporters pGL3ti-850 (+447/+1294) and pGL3ti-250 (+1037/+1294) from the first 
intron of the TMEPAI gene. (B) HepG2 cells were transfected with pGL3ti-850 or pGL3ti-250, 
and stimulated with EGF (10 ng/ml), TGF-β (0.1 ng/ml), or both EGF (10 ng/ml) and TGF-β 
(0.1 ng/ml) for 18 hours. (C) Schematic representation of the pGL3ti-250 with/without 
mutations on ELK-1 binding elements. Dot-line circles indicate possible ELK-1 binding sites. 
HepG2 cells were transfected with the mutant pGL3ti-250 reporters, as indicated, and 
stimulated with TGF-β (0.1 ng/ml), or TGF-β (0.1 ng/ml) and EGF (10 ng/ml), as indicated. (*P 
< 0.05) 
 
 
2-3-5 Binding of ELK-1 to Smad3 and ELK-1 binding sites in first intron of the 
TMEPAI gene. TGF-β-inducible target genes expression frequently requires the 
binding of Smad, which is activated by TGF-β, with coactivating transcription factors. I 
therefore examined the interaction between ELK-1 and Smad3 by coprecipitation assay, 
and revealed that ELK-1 actually interacted with Smad3 (Fig. 10A). I further 
investigated the binding of ELK-1 and Smad3 to the target sequence by chromatin 
immunoprecipitation (ChIP) assay using anti-ELK-1 and anti-Smad3 antibodies. The 
interaction of ELK-1 and Smad3 to the 250 bp sequence in the first intron of the 
TMEPAI gene could be detected upon EGF and TGF-β stimulation, respectively (Fig. 
10B, 10C). Taken together, co-stimulation with EGF and TGF-β activates the binding of 
ELK-1 and Smad3 in the first intron of the TMEPAI gene and strongly activates the 
target gene expression in the presence of ELK-1-Smad3 interaction.  
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Figure 10: ELK-1 binds to the first intron of TMEPAI gene in response to EGF 
stimulation. (A) Interaction of ELK-1 with Smad3. Smad 3 was immunoprecipitated by anti 
FLAG antibody, and coimmunoprecipitated ELK-1 was detected by anti ELK-1 antibody (top 
panel), the whole cell lysates were subjected to western-blotting to detect the expression of 
Smad3, and ELK-1. β-actin was used as the loading control. (B, C) HaCaT cells were treated 
with EGF (10 ng/ml, E), TGF-β (0.1 ng/ml, T), or both EGF (10 ng/ml) and TGF-β (0.1 ng/ml) 
(ET) for 1 hour, as indicated. 
 
 
2-4  Discussion 
 Since TGF-β signaling maintains a wide variety of cellular functions, un-controlled 
TGF-β signal results in many diseases and a prominent one being cancer. There is much 
evidence that TGF-β has functioned as both tumor suppressor by causing growth arrest 
and as a tumor promoter by promoting the invasion and migration of cancer cells via 
induction of EMT, recruiting new blood vessels to tumor sites (angiogenesis) and 
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suppression of the immune system (Masagué, 2008). The conflicting roles of TGF-β 
during tumor progression seem to occur in a tumor state-dependent manner. 
Nevertheless, much is still unknown on how TGF-β converts from being a tumor 
suppressor to a tumor promoter, stimulating research in this area.  
 On the other side, knockdown of TMEPAI results in tumor suppressive events 
including increased p27 expression, decreased HIF-1α, and VEGF expression via 
regulation of PI3K/PTEN/AKT pathway (Prajjal et al., 2010). Our previous study 
demonstrated that TMEPAI can interact with either Smad2 or Smad3 via its Smad 
interaction motif (SIM) in order to attenuate TGF-β/Smad pathway. Therefore, 
prolonged constitutive expression of TMEPAI would dampen TGF-β signaling and put 
cells at risk of aberrant growth.  
 Nakano et al. previously reported that TGF-β and Wnt signaling co-regulate the 
expression of TMEPAI via binding of Smads and TCF7L2 (transcription factor in Wnt 
signaling) to three Smad binding elements and a TGF-β-inducible TCF7L2 binding 
element in the first intron of TMEPAI gene (Nakano et al., 2010). However, this is 
merely a partial mechanism on constitutive expression of TMEPAI in cancer cells. Thus, 
it is of high importance to investigate deeper the mechanism of TMEPAI expression, for 
the targeted therapy in TMEPAI over-expressing cancers. 
 In the current study, I examined the role of EGF cross-regulation to TGF-β signaling 
on TMEPAI expression. Although by itself EGF signaling barely affects the expression 
of TMEPAI, EGF signaling strongly enhances the TGF-β induced TMEPAI expression, 
in comparison with HaCaT cells which were treated with TGF-β alone. Furthermore, 
HaCaT RasG12V transformed cells induced much higher level of TMEPAI protein and 
this was suppressed by EGFR inhibitor and MEK inhibitor. These data suggest that 
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EGFR/Ras/MEK pathway is essential for the expression of TMEPAI. The collaboration 
of EGF and TGF-β activates the pGL3ti-850 reporter which was constructed with 
mouse TMEPAI first intron (+447 to +1294) inserted upstream of the luciferase coding 
region. However, this signaling collaboration could not activate TMEPAI promoter (-
1972 to +67) reporter. Since it was reported that the AP-1 transcription factors such as 
c-Jun and c-Fos contributes synergistically transcriptional activation of PAI-1 gene in 
response to TGF-β, I investigated the involvement of AP-1 family on TMEPAI 
transcriptional activation. But I could not see the cooperative effect of AP-1 and TGF-β 
signaling on pGL3ti-850 reporter.  
 In contrast, co-expression of transcription factor, ELK-1 (which was activated by 
MEK) could promote TGF-β induced-pGL3ti-850 reporter activation. Subsequently, the 
first intron sequence from +1037 to +1294 region was essential for its binding leading 
to cooperative activation by EGF and TGF-β signaling. The mutation of ELK-1 binding 
site totally abolished the enhancement of TGF-β-induced reporter activity by EGF. On 
the other hand, it was reported that EGF signaling directly phosphorylates and inhibits 
Smad functions. Therefore, I examined the effect of EGF on (SBE)4-luc reporter that is 
directly activated by the TGF-β/Smad signaling pathway. As a result, I could not detect 
any influence of EGF signaling on (SBE)4-luc activity (data not shown), suggesting that 
in this cell context EGF signaling does not inhibit R-Smads function. Thus, ELK-1 
could be a partner of Smad and co-regulate TMEPAI transcription.  Indeed, ELK-1 
interacts with Smad3. Chromatin immunoprecipitation data showed that both ELK-1 
and Smad3 bind to the first intron of TMEPAI gene in an EGF and TGF-β dependent 
manner for activation of TMEPAI transcription.  
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 My proposed mechanism on TMEPAI regulation by EGF and TGF-β signaling may 
provide as part of the factors leading to dual roles of TGF-β in cancer progression.  
Taking lung cancer as an example whereby TGF-β signaling functions to suppress cell 
proliferation, this growth inhibitory mechanism could be circumvented by cancer cells 
by taking advantage of active EGF signaling and ELK-1 to alleviate restrictions on 
TMEPAI expression. High TMEPAI expression keeps TGF-β signaling to a minimum 
level that is insufficient for tumor growth inhibition while its autocrine signaling is still 
able to induce cell invasion and cancer cell dissemination.    
 In conclusion, both TGF-β and EGF signaling coordinately regulate the transcription 
of TMEPAI via activation of Smad3 and ELK-1 on the first intron of the TMEPAI gene.  
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CHAPTER 3:  
TMEPAI enhances Tumorigenic Activities in Lung Cancer Cells 
 
 
3-1 Introduction 
High levels of TMEPAI expression have been reported in renal cell carcinoma, colon 
cancer, breast cancer, and ovarian cancer as well as in several cancer cell lines (Rae et 
al., 2001; Giannini et al., 2003; Brunschwig et al., 2003). Genomewide studies, which 
compared the gene expression levels of invasive cancer tissues with normal counterpart 
tissues or preinvasive cancers, suggested that TMEPAI is one of the most highly 
inducible genes in invasive cancers (Saadi et al., 2010; Rajkumar et al., 2010). TMEPAI 
was further suggested as a “molecular switch” that converts TGF-β signaling from a 
tumor suppressor to a tumor promoter (Rae et al., 2001). These lines of evidence 
suggest an oncogenic function of TMEPAI in many cancers. However, how TMEPAI 
regulates tumor progression remains largely unknown. In this study, I aimed to 
investigate the tumorigenic activities of TMEPAI in lung cancer cell lines.  
 
 
3-2  Materials and methods 
3-2-1 Cell culture. HaCaT cells (spontaneously immortalized human keratinocyte cell 
line) and COS7 cells (African green monkey kidney cells transformed by SV40) were 
cultured in Dulbecco`s modified Eagle’s medium (Sigma) containing 10% fetal calf 
serum (FCS, Invitrogen), penicillin streptomycin solution. NCI-H23 and RERF-LC-KJ 
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cells were cultured in RPMI 1640 medium containing 10% FCS, penicillin streptomycin 
solution. Calu3 cells and HepG2 cells were cultured in minimum essential medium 
(Sigma) containing 10% FCS, penicillin streptomycin solution. Nontargeting shRNA 
(SHC002), TMEPAI shRNA#9, and TMEPAI shRNA#10 ligated in a pSUPER RNAi 
system (Oligoengine) were used for knockdown of TMEPAI. For the selection of stable 
TMEPAI-knockdown clones, Calu3 or NCI-H23 cells were cultured in the presence of 
0.6 µg/ml or 1 µg/ml of puromycin (Sigma), respectively. The TGF-β receptor kinase 
inhibitor SD208 (Bioscience) and anti-TGF-β neutralizing antibody (R&D Systems) 
were used to block TGF-β signaling. 
 
shRNA Sequence  
Non-targeting SHC002 (Sigma) 
sh RNA # 9 CCG GGA GCA AAG AGA AGG ATA AAC ACT CGA 
GTG TTT ATC CTT CTC TTT GCT CTT TTT 
sh RNA # 10 CCG GGA GTT TGT TCA GAT CAT CAT CCT CGA 
GGA TGA TGA TCT GAA CAA ACT CTT TTT 
 
 
3-2-2 Luciferase assay. HepG2 cells were transfected with (CAGA)12-luc using 
FuGENE6 (Roche Diagnostics), treated with TGF- or 50% v/v of heat-treated serum-
free conditioned media (80
0
C, 10 minutes) after 24 hours incubation with HaCaT or 
lung cancer cell lines. Luciferase activities were determined as described in [2-2-3].  
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3-2-3 Western-blotting. Endogenously expressed TMEPAI in HaCaT or lung cancer 
cell lines was detected by western-blotting using total cell lysates with/without TGF-β 
stimulation. The assay was carried out as described in [2-2-4]. Antibodies were used as 
follow:  
1
st
 antibody : mouse anti-TMEPAI antibody (x 1000)  
 (homemade monoclonal antibody) (Vo Nguyen et al., 2014) 
 rabbit anti-Smad2/3 antibody (BD Bioscience) (x 1000) 
 rabbit anti-phosphorylated Smad2 (PS2) antibody  
 (Persson et al., 1998) (x 1000) 
 mouse anti-β-actin antibody (Sigma) (x 5000) 
2
nd
 antibody  : anti mouse-IgG-(horseradish peroxidase; HRP) 
 (GE Healthcare) (x 10000) 
 anti rabbit-IgG-HRP (GE Healthcare) (x 10000) 
 
3-2-4 Immunofluorescence staining. HaCaT and NCI-H23 cells were cultured on glass 
coverslips, fixed with 4% paraformaldehyde-PBS, permeabilized with 0.3% Triton X-
100/PBS, and incubated with 1% bovine serum albumin. Cells were then incubated with 
antibodies, and the nuclei were stained with Hoechst 33342 (Sigma). Intracellular 
localization was then observed by fluorescence microscopy (Axiovert 200; Zeiss).   
 
1
st
 antibody  : mouse anti-TMEPAI antibody (x 250)  
 (homemade monoclonal antibody) (Vo Nguyen et al., 2014) 
2
nd
 antibody  : goat Alexa888 anti-mouse IgG- (Molecular Probes) (x 250)  
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3-2-5 Cell proliferation assay. Cells were seeded in 24-well plates, cultured for the 
indicated time periods, and counted with a hematocytometer. 
 
3-2-6 Sphere formation assay. Spheres were cultured in DMEM/F12 serum-free 
medium (Invitrogen) supplemented with B27 (Invitrogen), 20 ng/ml of EGF (Sigma), 
and 20 ng/ml of bFGF (R&D Systems) in an ultra-low attachment culture dish 
(Corning). 
 
3-2-7 In vivo tumor formation assay. For cancer cell implantation, 10
7
 cells were 
subcutaneously injected into 8-week-old female nonobese diabetic/severe combined 
immunodeficiency mice (NOD-SCID mice). After 3 months, the mice were sacrificed 
and the tumors were weighed. All animal experiments were approved by the animal 
experiment committee of the University of Tsukuba and performed in accordance with 
the university’s animal experiment guidelines and the provisions of the Declaration of 
Helsinki in 1995. 
 
3-3-8 In vivo lung metastasis assay. A suspension containing 10
6
 cells in 0.2 ml of 
PBS was injected into the lateral tail vein of 7-week-old NOD-SCID mice. After 8 
weeks, the animals were sacrificed and the removed lungs were fixed in 10% 
neutralized formalin solution, embedded in paraffin, sliced into 3-µm sections, and 
stained with hematoxylin and eosin or immunostained with Ki-67 antibody 
(Novocastra). Three animals were used in each group. The tumor areas in a 
representative cut surface were measured with an Olympus Virtual Slide System and 
with ASW morphometry software (Olympus).  
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3-3  Results 
3-3-1 Enhanced and constitutive expression of TMEPAI in lung cancer cell lines. I 
evaluated TMEPAI expression levels in the human lung adenocarcinoma cell lines 
Calu3, NCI-H23, and RERF-LC-KJ. HaCaT cells were used as a positive control. 
HaCaT cells expressed detectable levels of TMEPAI only in the presence of more than 
8 hours of TGF-β stimulation; there were no detectable levels of TMEPAI without 
TGF- stimulation (Fig. 11A). In contrast, all 3 of the examined lung cancer cell lines 
expressed detectable levels of TMEPAI even in the absence of TGF-β stimulation. 
Notably, Calu3 constitutively expressed high levels of TMEPAI, whereas NCI-H23 and 
RERF-LC-KJ expressed distinct but relatively low levels of TMEPAI and enhanced 
TMEPAI expression about twofold in response to TGF-β (Fig. 11B). Endogenous 
TMEPAI could also be detected as cytoplasmic dot patterns in HaCaT and NCI-H23 
cells by immunofluorescence staining (Fig. 11C).  
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Figure 11: Enhanced expression of TMEPAI in lung cancer cells. (A) Induction of TMEPAI by 
5 ng/ml of TGF-β in HaCaT cells. Endogenous TMEPAI was detected by a monoclonal anti-
TMEPAI antibody. β-actin was used as the loading control. Relative expression levels of 
TMEPAI/β-actin were detected by densitometry and indicated below the panels. (B) Expression 
of TMEPAI in the lung cancer cell lines Calu3, RERF-LC-KJ, and NCI-H23 detected as in (A). 
(C) HaCaT or NCI-B23 cells were treated with 5 ng/ml of TGF-β as indicated. After treatment, 
the cells were subjected to fluorescence microscopy using anti-TMEPAI antibody.  
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3-3-2 TGF-β signaling mediates the enhanced expression of TMEPAI in lung 
cancer cells. The high expression levels of TMEPAI in lung cancer cells prompted us to 
examine how TMEPAI expression is constitutively enhanced in these cells. To 
investigate the possibility that TGF-β signaling is involved in TMEPAI expression, cells 
were treated with the TGF-β receptor kinase inhibitor SD208 or anti-TGF-β neutralizing 
antibodies. TMEPAI disappeared from all cell lines in the presence of SD208 (Fig. 
12A). While the effects of the TGF-β neutralizing antibodies were not complete, they 
did cause the TMEPAI levels to significantly decrease to levels correlating with Smad2 
phosphorylation levels in all 3 cell lines (Fig. 12B). I further examined TGF- activities 
in the conditioned media incubated 24 hours with the lung cancer cells. Calu3 secreted 
abundant TGF- in the culture media and it had positive correlation with the levels of 
TMEPAI expression (Fig. 12C) 
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Figure 12: TGF-β signaling mediates the expression of TMEPAI in lung cancer cell lines Calu3, 
NCI-H23, and RERF-LC-KJ. (A) The TGF-β receptor kinase inhibitor SD208 (1 µM) or (B) a 
TGF-β neutralizing antibody (5 µg/ml) were added 1 hour before stimulation with 5 ng/ml of 
TGF-β for 8 hours as indicated. Then, the cell lysates were subjected to immunoblot analysis. 
TMEPAI was detected by using anti-TMEPAI antibody and the levels of phosphorylated Smad2 
were detected with anti-phosphorylated Smad2 antibody (PS2). β-actin was used as the loading 
control. (C) TGF-β activities in the serum-free conditioned media after 24 hours incubation with 
the indicated cells were measured by (CAGA)12-luc reporter assay. The means ± SDs are shown. 
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3-3-3 Knockdown of TMEPAI enhances Smad phosphorylation and growth 
inhibitory responses of TGF-β. I next engineered stable knockdown of TMEPAI by 
two individual shRNAs (shTMEPAI#9 and shTMEPAI#10). These shRNAs 
significantly reduced TMEPAI expression in Calu3 cells (Calu3-sh#9 and Calu3-sh#10; 
Fig. 13A). As a result, phosphorylated Smad2 levels were clearly enhanced (Fig. 13B). 
Significantly stronger cell growth inhibition was obtained in Calu3-sh#9 and Calu3-
sh#10 cells in the presence of 0.1 ng/ml of TGF-β, and it was recovered by anti-TGF- 
neutralizing antibodies (Fig. 13C, 13D).  
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Figure 13: Calu3-shTMEPAI cells have increased sensitivity to TGF-β. (A) Generation of 
TMEPAI-knockdown Calu3 cell lines. The expression of TMEPAI was significantly suppressed 
by stable expression of two independent shRNAs (#9 and #10) targeting TMEPAI mRNA. Cells 
were treated with TGF-β for 8 hours, and endogenous TMEPAI was detected by western-
blotting. β-actin was used as the loading control. (B) Cells were stimulated with TGF-β (1 
ng/ml) for 1 hour and phosphorylated Smad2 was detected with anti-phosphorylated Smad2 
antibody (PS2). β-actin was used as the loading control. (C, D) Cell proliferation assay. (C) 
TMEPAI-knockdown Calu3 cells (Calu3 sh#9 and Calu3 sh#10) were cultured in 12-well plate 
without TGF-β (left), with TGF- (0.1 ng/ml) (middle) or with TGF- (0.1 ng/ml) and TGF- 
neutralizing antibody (1 ng/ml) (right), as indicated. The cell numbers were counted every 
second day. The means ± SDs are shown. (D) Mean % growth inhibition by TGF- (0.1 ng/ml) 
and the reversal by the inclusion of TGF- neutralizing antibody (1 ng/ml) was calculated on 
day 9 in each cell lines.  
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3-3-4 TMEPAI enhances sphere-forming activities. I further investigated the 
functional significance of TMEPAI in the sphere-forming activities. The sphere-forming 
activities of TMEPAI-knockdown cells were significantly reduced in Calu3 cells (Fig. 
14A, 14B).   
 
 
 
 
Figure 14: Calu3-shTMEPAI cells have decreased sphere-forming activities. (A) Control and 
TMEPAI-knockdown Calu3 cells (Calu3 sh#9 and Calu3 sh#10) were cultured in sphere 
formation medium for 12 days. Typical photographs are shown. (B) The numbers of spheres 
larger than 100 µm in diameter were counted. The means ± SDs are shown. *P < 0.01 (vs 
control). 
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3-3-5 TMEPAI enhances in vivo tumor formation. In addition, I performed xenograft 
assays in NOD-SCID mice. Calu3, Calu3-shcontrol, Calu3-sh#9 and Calu3-sh#10 cells 
were subcutaneously injected into NOD-SCID mice. Three months after injection, the 
tumors were collected and weighed. As shown in Fig. 15, the tumors of the Calu3-sh#9 
and -sh#10 cells were significantly smaller than those of the control cells in NOD-SCID 
mice.    
 
 
 
 
Figure 15: Calu3-shTMEPAI cells have decreased tumor-forming activities. (A) Calu3, Calu3-
shcontrol and TMEPAI-knockdown Calu3 cells (Calu3-sh#9 and Calu3-sh#10) were 
subcutaneously injected into NOD-SCID mice with Matrigel supplement. After 3 months, the 
tumors were harvested and photographed. (B) The tumors were weighed. The means ± SDs are 
shown. *P < 0.01 (vs control).  
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3-3-6 TMEPAI enhances metastatic tumor formation in lungs. To examine the 
effects of TMEPAI on the metastatic potential in lungs, I injected Calu3, Calu3-
shcontrol, Calu3-sh#9 and -sh#10 cells into the tail veins of NOD-SCID mice. Eight 
weeks after injection, mice were sacrificed and the collected lungs were examined 
histopathologically with hematoxylin and eosin staining. I also stained for Ki-67 to 
detect proliferating cancer cells. Using morphometric software, I calculated the 
percentage of the representative tumor areas in the total lung areas. Calu3-sh#9 and 
Calu3-sh#10 cells formed significantly smaller tumors both is size and numbers than 
those of the control Calu3 cells (Fig. 16A-D). These results indicated that knockdown of 
TMEPAI suppresses the ability of lung cancer cells to develop metastatic tumors in 
lungs.  
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Figure 16: Calu3-shTMEPAI cells have decreased tumorigenic activity in the lungs. Calu3, 
Calu3-shcontrol and TMEPAI-knockdown Calu3 cells (Calu3-sh#9 and Calu3-sh#10) were 
injected into the tail vein of NOD-SCID mice (10
6
 cells in 200 µl PBS/ mice). (A) After 8 
weeks, the lungs were collected and photographed. (B) The thin sections of lungs were stained 
with hematoxylin and eosin. Scale bars = 1 mm. Higher magnifications show a typical 
metastatic area. (C) The percentages of tumor areas were measured by image analyses as 
described in the Materials and Methods. The means ± SDs are shown. *P < 0.01 (vs control). 
(D) The same lung sections as those in (B) were stained with anti-Ki67 antibodies. The nuclei of 
proliferating cancer cells showed positive staining. Scale bars = 100 µm. 
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3-4 Discussion 
 Transmenbrance prostate androgen induced protein (TMEPAI) is one of responsible 
protein of TGF-β signaling upon induction. Previous studies demonstrated that TMEPAI 
is highly expressed in various cancers such as renal cell carcinoma, colon cancer, breast 
cancer, and ovarian cancer (Rae et al., 2001; Giannini et al., 2003; Brunschwig et al., 
2003). Genomewide studies, which compared the gene expression levels of invasive 
cancer tissues with normal counterpart tissues or preinvasive cancers, suggested that 
TMEPAI is one of the most highly inducible genes in invasive cancers (Saadi et al., 
2010; Rajkumar et al., 2010). Furthermore, dysregulation of TGF-β signaling was 
identified as an important mediator of lung cancer invasion (Toonkey et al., 2010). 
Therefore, I examined the expression of TMEPAI in lung cancer cell lines. Both 
immunoblot and immunofluorescent analyses clearly detected high levels of TMEPAI 
expression in all 3 examined lung cancer cell lines.  
 The mechanism of enhanced TMEPAI expression in cancer cells is an important 
issue to be elucidated. Oncogenes can be activated by gene amplification and other 
mechanisms. Human chromosomal region 20q13, on which the TMEPAI gene is located, 
is frequently amplified in breast cancers (Tanner et al., 1994; Courjal et al., 1996). 
Expression of TMEPAI in lung cancer cells disappeared in the presence of a TGF-β 
receptor kinase inhibitor and was significantly suppressed by anti-TGF-β neutralizing 
antibodies. Although Calu3 cells expressed high levels of TMEPAI in the absence of 
detectable Smad2 phosphorylation, expression of TMEPAI was significantly suppressed 
by a TGF-β receptor kinase inhibitor. Nakano et al. reported that Smad3 and Smad4 are 
essential for the TGF-β-inducible expression of TMEPAI (Nakano et al., 2010). On the 
other hand, it is also known that the expression of TMEPAI is enhanced by Wnt, 
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EGFR/Ras/MAPK, androgen and mutant p53 as shown by us and others (Xu et al., 
2000; Giannini et al., 2003; Anazawa et al., 2004; Muñoz et al., 2006; Nakano et al., 
2010). The effects of SD208 in Fig. 12A indicate that activity of type I TGF-β receptor 
kinase is required for the stable expression of TMEPAI in lung adenocarcinoma cells. 
Moreover, many of these cells usually have activated EGFR/RAS/MAPK signaling, 
even if Smad2 phosphorylation is underdetectable levels in immunoblot analysis. These 
results suggest that cancer cells can maintain TMEPAI expression by multiple 
oncogenic signaling to suppress Smad phosphorylation down to under detectable levels 
but even in these cases TGF-β receptor kinase activity is required to support TMEPAI 
expression. The contributions of synergistic effects of multiple oncogenic signaling 
including the role of TGF-β non Smad signaling pathway in cancer cells must be 
elucidated in the future.  
 The functions of TMEPAI in cancer cells are the next important issue to be examined. 
Recent reports indicated that knockdown of TMEPAI suppresses the tumorigenic 
activities of breast cancer cells and androgen receptor-negative prostatic cancer cells 
(Prajjal et al., 2010; Liu et al., 2011). Here, I showed that knockdown of TMEPAI in 
lung cancer cells potentiates TGF-β-inducible Smad phosphorylation and growth 
inhibitory responses to TGF-β (Fig. 13). Consequently, the sphere-forming activity in 
vitro, subcutaneous tumor formation, and lung metastasis were significantly suppressed 
in NOD-SCID mice (Fig. 15, 16). Liu et al. reported that knockdown of 
PMEPA1/TMEPAI suppresses the Smad3/4-cMyc-p21
Cip1
 pathway in AR-negative 
prostatic cancer cells. These effects can be explained by the suppressive function of 
TMEPAI on Smad signaling via its SIM domain (Liu et al., 2011). However, Prajjal et al. 
identified suppression of Akt phosphorylation and expression of HIF1β and VEGF in 
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TMEPAI-knockdown xenograft breast tumors (Prajjal et al., 2010). These effects may 
be independent from the Smad regulatory function of TMEPAI. Both TMEPAI and its 
family molecule C18ORF1 share tandem PY motifs interposing a SIM domain. The 
possibility of another TMEPAI function such as that indicated by Prajjal et al. may 
explain the reason for TMEPAI’s involvement among multiple regulators of Smad 
signaling in outstandingly divergent cancers. Further studies will be required to reveal 
the overall functions of TMEPAI in cancer development.  
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CHAPTER 4: PERSPECTIVES 
 
 
4-1 Oncogenic function of TMEPAI and its application in cancer therapy. 
 TGF-β-induced TMEPAI is highly expressed in many cases of human cancer and 
TMEPAI participates in the negative feedback regulation of TGF-β/Smad signaling. 
There are several other negative feedback regulators of TGF-β/Smad pathway, such as 
Smad7, smurf2 and SnoN. Among these regulators, TMEPAI has strong and direct 
correlation with carcinogenic activities (Watanabe et al., 2010). TMEPAI has been 
shown to be highly expressed in many cases of cancer and knockdown of TMEPAI 
efficiently suppresses tumorigenic activities. Therefore, I speculated that TMEPAI may 
have additional function other than the suppression of TGF-β/Smad signaling, which 
might cause oncogenic signaling. I recently found that the phosphorylation of AKT 
serine 473 was strongly reduced in TMEPAI knockdown Calu3 cells, whereas, the other 
phosphorylation site threonine 308 did not (Fig. 17). It`s well-documented that the fully 
activation of AKT required the phosphorylation of two important amino acid residues 
threonine 308 and serine 473, which is negatively regulated by phosphatases PTEN and 
PHLPP1, respectively (Manning and Cantley, 2007; Brognard and Hunter, 2011; Liu et 
al., 2009, 2011). The AKT signaling regulates cell growth, proliferation and survival, 
angiogenensis, cell motilities, and glucose metabolism. The frequent hyperactivation of 
AKT signaling is observed in many human cancer, and aberrant regulation of these 
processes are considered the hallmarks of cancer (Chin and Toker, 1996; Shayesteh et 
al., 1999; Ma et al., 2000; Vivanco and Sawyers, 2002; Altomare and Testa, 2005). My 
preliminary data showed that knockdown TMEPAI suppressed AKT phosphorylation 
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leads to the idea that TMEPAI possibly affect PI3K/AKT signaling. Indeed, I found that 
the endogenous PHLPP1 was relatively low in Calu3 cells, but high in TMEPAI 
knockdown Calu3 cells (data not shown), indicated that TMEPAI might reduce the 
protein levels of PHLPP1, and could be involved in the regulation of AKT 
phosphorylation at serine 473. There is a possibility that TMEPAI promotes PHLPP1 
degradation via its two PY motifs, which can interact with HECT type E3 ubiquitin 
ligases such as NEDD4. Furthermore, the transcription factors Sp1 and Smad3 have 
been reported to bind to the PHLPP1 promoter sequence and increase expression of the 
PHLPP1 gene (Dong et al., 2013; ÓNeilll et al., 2013). TMEPAI negatively regulates 
TGF-β; therefore, TMEPAI might be involved in the transcriptional regulation of 
PHLPP1 through the suppression of TGF-β/Smad3 signaling. Further studies will be 
required to reveal the novel function of TMEPAI on regulating AKT signaling. 
Targeting on TMEPAI could be considered as a potential molecularly targeted strategy 
in cancer therapy.  
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Figure 17: Knockdown of TMEPAI supresses AKT phosphorylation at Serine 473. Control 
and TMEPAI knockdown Calu3 lung cancer cells, as indicated, were treated with EGF (50 
ng/ml) for 0.5 or 12 hours. Then the cell lysates were subjected to western-blotting detecting 
Akt, phosphorylated Akt at Thr308, and phosphorylated Akt at Ser473. β-actin was used as the 
loading control. Results of densitometry p-Akt (ser473)/-actin was indicated below the 
corresponding panels (arbitrary units; control = 1).   
 
4-2  Application of TMEPAI Monoclonal antibody in cancer diagnosis.  
 Previous studies demonstrated that TMEPAI was highly expressed in various 
cancers such as colon cancer, breast cancer and ovarian cancer. Here we showed that 
lung cancer cell lines also give high levels of expression. High levels of TMEPAI 
expression lead us an idea to use TMEPAI as a tumor marker for cancer diagnosis. In 
general, tumor markers are secreted or flew out from cancer cells, and the serum 
concentration detected by “blood test” would increase with cancer progression. Several 
proteins and sugar chains were already being used as tumor markers; for example 
carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), CA 125, or prostate-
specific antigen (PSA). Genome wide studies, which compared the gene expression 
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levels between cancer tissues and normal counterparts, suggested that TMEPAI is one 
of the highest inducible genes in cancer. On the other hand, tissue distribution of 
TMEPAI remains unclear; the tissue staining method by using established antibodies 
for TMEPAI will provide the fundamental information for physiological and 
pathological roles of TMEPAI. The tissue samples from cancer patients will be used to 
investigate the tissue distribution of TMEPAI.  
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CHAPTER 5: CONCLUSIONS 
 
 
 The cellular function and tissue homeostasis is tightly controlled by the interwoven 
signaling network inside the cell (Guo and Wang, 2009). Disruption of the balance of 
these networks leads to develop various diseases, including cancers. In this work, I 
revealed the transcript regulation as well as tumorigenic function of TMEPAI, one of the 
responsive target gene of TGF-β signaling. TMEPAI is induced by TGF-β signaling, and 
joins to the negative feedback loop to control the duration and intensity of TGFβ/Smad 
signaling by sequestering Smad2/3 from ligand-induced phosphorylation (Watanabe et 
al., 2010). The transcription of TMEPAI has been reported to be regulated not only by 
TGF-β/Smad signaling, but also by the other signaling, for instance EGF, mutant p53, 
and Wnt signaling. Nakano et al. reported the synergy between TGF-β and Wnt 
signaling in the regulation of the TMEPAI expression by recruiting the transcription 
factor TCF7L2 and Smad3 to the enhancer within the first intron of the TMEPAI gene 
(Nakano et al., 2010). Interestingly, beside several TGF-β-responsive TCF7L2-binding 
elements (TTE), which are activated upon Wnt/β-catenin signaling activation, I could 
find there are three EGF-induced transcription factor ETS binding sites also located 
within the first intron of the TMEPAI gene. Co-stimulation between TGF-β and EGF 
cooperatively increased the TMEPAI transcripts, and mutation of these ETS-binding 
sites resulted in suppression of TMEPAI expression. These data suggest that the 
transcripts of TMEPAI are controlled by a crosstalk signaling networks between TGF-β, 
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EGF, and Wnt signaling. However, other signaling might also be involved in TMEPAI 
regulation and should be further investigated for better understating.  
 On the other hand, TMEPAI has been reported to be highly expressed in many 
cancers, and knockdown TMEPAI in human lung cancer Calu3 cells inhibited cell 
growth and tumor formation, suggesting the tumorigenic function of TMEPAI (Vo 
Nguyen et al., 2014). The mechanism how TMEPAI involved in cancer progression also 
gives the interesting point for this molecule. There are many informative discussion 
reported for the tumorigenic function of TMEPAI. For example, TMEPAI can suppress 
the growth-inhibition activity of TGF-β, TMEPAI can convert TGF-β from a tumor 
suppressor to a tumor promoter (Prajji et al., 2010; Bai et al., 2014), or my recent 
hypothesis that TMEPAI might sustain the activity of PI3K/AKT signaling by the 
suppression the AKT-negative-regulator PHLPP1 phosphatase. The investigation about 
the mechanism how TMEPAI can mediate such signaling regulator proteins will 
probably prompt us to be able to find novel function of TMEPAI. For this purpose, the 
rescue experiments which re-express TMEPAI containing functional domain mutations 
in TMEPAI knockdown cancer cells should be carried out. 
  In addition, besides the major-signaling molecules of TGF-β, there are many 
proteins that interact with the signaling molecules and form impeccable signal network 
inside the cell. They may play an important role in both positive and negative regulation 
of TGF-β signaling pathway. Identification of the TMEPAI–interacting proteins 
networks and their mediated function would give more interesting evidences to get 
insights into the molecular mechanism for fine regulation of TGF-β-induced TMEPAI 
in cancer cells. 
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 Finally, high levels of TMEPAI expression suggest an idea to use TMEPAI as a 
tumor marker for cancer diagnosis. Therefore, if the levels of TMEPAI can be detected 
in cancer patients, it will be useful for early and easy detection of cancer relapse.  
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